This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheng, G. Articles by Fukuda, T. Search for Related Content PubMed PubMed Citation Articles by Cheng, G. Articles by Fukuda, T.

Anti–Interleukin-9 Antibody Treatment Inhibits Airway Inflammation and Hyperreactivity in Mouse Asthma Model

Department of Pulmonary Medicine and Clinical Immunology, Dokkyo University School of Medicine, Tochigi, Japan

Correspondence and requests for reprints should be addressed to Takeshi Fukuda, M.D., Ph.D., Departments of Pulmonary Medicine and Clinical Immunology, Dokkyo University School of Medicine, Mibu-machi, Shimotsuga-gun, Tochigi, 321–0293, Japan. E-mail: cheng{at}dokkyomed.ac.jp

Numerous in vitro and in vivo studies in both animals and patients with asthma have shown that interleukin (IL)-9 is an important inflammatory mediator in asthma. To examine the effects of IL-9 antagonism on airway inflammation, ovalbumin-sensitized BALB/c mice were intravenously given anti–IL-9 antibody or an isotype-matched control antibody 30 minutes before challenge with aerosolized ovalbumin. Airway response to methacholine was measured, and samples of bronchoalveolar lavage fluid (BALF) were obtained 24 hours after the last antigen challenge. Lung tissue was harvested and examined histopathologically. After ovalbumin challenge, there were significant increases in airway hyperreactivity, the numbers of inflammatory cells in lung, and IL-4, IL-5, and IL-13 production in BALF. Treatment with anti–IL-9 antibody significantly prevented airway hyperreactivity in response to methacholine inhalation. Blockade of IL-9 reduced the numbers of eosinophils (0.3 ± 0.1 x 10⁵ and 23.6 ± 0.5 x 10⁵/ml, anti–IL-9 antibody/control immunoglobulin G) and lymphocytes (0.2 ± 0.2 x 10⁵ and 0.8 ± 0.1 x 10⁵/ml) in BALF. Anti–IL-9 antibody treatment also reduced the concentrations of IL-4 (from 70.6 ± 4.6 to 30.8 ± 5.2 pg/ml), IL-5 (from 106.4 ± 12 to 54.4 ± 6.6 pg/ml), and IL-13 (from 44.2 ± 7.6 to 30.1 ± 5.5 pg/ml) in BALF. Macrophage-derived cytokine expression in the airways was also decreased by IL-9 blockade. Taken together, our findings emphasize the importance of IL-9 in the pathogenesis of asthma and suggest that blockade of IL-9 may be a new therapeutic strategy for bronchial asthma.

Key Words: interleukin-9 • eosinophils • asthma • airway hyperreactivity • mouse

This article has been cited by other articles:

				S. van den Brule, J. Heymans, X. Havaux, J.-C. Renauld, D. Lison, F. Huaux, and O. Denis Profibrotic Effect of IL-9 Overexpression in a Model of Airway Remodeling Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 202 - 209. [Abstract] [Full Text] [PDF]

				V. Steenwinckel, J. Louahed, C. Orabona, F. Huaux, G. Warnier, A. McKenzie, D. Lison, R. Levitt, and J.-C. Renauld IL-13 Mediates In Vivo IL-9 Activities on Lung Epithelial Cells but Not on Hematopoietic Cells J. Immunol., March 1, 2007; 178(5): 3244 - 3251. [Abstract] [Full Text] [PDF]

				Y. Chiba, R. Kurotani, T. Kusakabe, T. Miura, B. W. Link, M. Misawa, and S. Kimura Uteroglobin-related Protein 1 Expression Suppresses Allergic Airway Inflammation in Mice Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 958 - 964. [Abstract] [Full Text] [PDF]

				L. Knoops, J. Louahed, J. Van Snick, and J.-C. Renauld IL-9 Promotes but Is Not Necessary for Systemic Anaphylaxis J. Immunol., July 1, 2005; 175(1): 335 - 341. [Abstract] [Full Text] [PDF]

				Y. Chiba, T. Kusakabe, and S. Kimura Decreased expression of uteroglobin-related protein 1 in inflamed mouse airways is mediated by IL-9 Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1193 - L1198. [Abstract] [Full Text] [PDF]

				A. S. Gounni, Q. Hamid, S. M. Rahman, J. Hoeck, J. Yang, and L. Shan IL-9-Mediated Induction of Eotaxin1/CCL11 in Human Airway Smooth Muscle Cells J. Immunol., August 15, 2004; 173(4): 2771 - 2779. [Abstract] [Full Text] [PDF]

				J. H. Edwan, G. Perry, J. E. Talmadge, and D. K. Agrawal Flt-3 Ligand Reverses Late Allergic Response and Airway Hyper-Responsiveness in a Mouse Model of Allergic Inflammation J. Immunol., April 15, 2004; 172(8): 5016 - 5023. [Abstract] [Full Text] [PDF]

				M. A. Aronica, S. McCarthy, S. Swaidani, D. Mitchell, M. Goral, J. R. Sheller, and M. Boothby Recall Helper T Cell Response: T Helper 1 Cell-resistant Allergic Susceptibility without Biasing Uncommitted CD4 T Cells Am. J. Respir. Crit. Care Med., March 1, 2004; 169(5): 587 - 595. [Abstract] [Full Text] [PDF]

				K. Honda, M. Arima, G. Cheng, S. Taki, H. Hirata, F. Eda, F. Fukushima, B. Yamaguchi, M. Hatano, T. Tokuhisa, et al. Prostaglandin D2 Reinforces Th2 Type Inflammatory Responses of Airways to Low-dose Antigen through Bronchial Expression of Macrophage-derived Chemokine J. Exp. Med., August 18, 2003; 198(4): 533 - 543. [Abstract] [Full Text] [PDF]

				M. J. Tobin Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 319 - 332. [Full Text] [PDF]